ClinicalTrials.gg
CompletedNCT03096639RESCUE2Updated Nov 16, 2022

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing

An interventional study of Diaphragmatic Pacing Therapy DPTS in Ventilator Induced Diaphragm Dysfunction, sponsored by Lungpacer Medical Inc.. Completed at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomized clinical trial to investigate the use of the temporary Diaphragm Pacing Therapy System (DPTS) to rehabilitate the diaphragm in mechanically ventilated patients who have failed at least two weaning attempts. The goal is to strengthen and rehabilitate the diaphragm to liberate the patient more quickly from mechanical ventilation.

Read the detailed description

Mechanical ventilation (MV) is a life saving technology but can also cause damage to the lungs and diaphragm such as ventricular induced diaphragmatic dysfunction (VIDD). Research has shown that after being on mandatory MV and sedated the diaphragm begins to atrophy within as short as 18 hours. The Lungpacer Diaphragm Pacing Therapy System (DPTS) is a temporary therapy that consists of the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) and the Lungpacer Control Unit system. The LIVE Catheter is a proprietary central venous catheter that incorporates pacing electrodes in strategic areas that align with the left and right phrenic nerves. The LIVE Catheter can also be used for fluid delivery like any other central venous catheter. The randomized clinical trial will investigate the safety, effectiveness and performance of the Lungpacer DPTS. By stimulating the diaphragm through daily therapy sessions, with the intention of exercising and rehabilitating the diaphragm muscle so the patient may be able to be more quickly liberated from MV. The patient population includes those who have been mechanically ventilated for greater than or equal to 96 hours (4days), have failed two or more spontaneous breathing trials (SBT), and were not hypervolemic during the latest spontaneous breathing trial. Patients must have resolution of the initial indication for placement on mechanical ventilation before entering the trial.

02

Conditions studied

  • Ventilator Induced Diaphragm Dysfunction

Keywords

  • Diaphragm atrophy
  • VIDD
  • Weaning failure
03

In context

Lead sponsor

Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • have been mechanically ventilated for > or = to 96 hours (4 days), and
  • have satisfied the Readiness-to-Wean criteria and
  • have failed at least two VLTs, one of which is the study specific VLT.

Exclusion criteria

Exclusion Criteria:

  • currently on extracorporeal membrane oxygenation (ECMO);
  • weaning failure due to hypervolemia;
  • medical history or known anatomy that prevents insertion of the LIVE Catheter into the left subclavian vein;
  • currently being treated with neuromuscular blockade;
  • clinically overt congestive heart failure that is preventing weaning;
  • pre-existing neuromuscular diseases that could affect the respiratory muscles;
  • pre-existing severe chronic pulmonary fibrosis;
  • pleural effusions occupying greater than one third of the pleural space on either side;
  • > or = 40;
  • known or suspected phrenic nerve paralysis;
  • any electrical device (implanted or external) that may be prone to interaction with or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
  • prior bacteremia reported within the last 48 hours;
  • current hemodynamic instability, sepsis or septic shock;
  • terminally ill with 6 months or less or not committed to full care;
  • known or suspected to be pregnant or lactating; and
  • currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    Diaphragm Pacing Therapy DPTS

    Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.

    Device: Diaphragmatic Pacing Therapy DPTS

  • No intervention
    Control Group

    Standard of care treatment of weaning failure, no intervention is involved in this control group.

Interventions

  • DeviceDiaphragmatic Pacing Therapy DPTS

    Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.

    Also known as: DPTS, LIVE Catheter

06

What researchers measure

Primary outcomes

  1. Proportion successfully weaned by 30 days for subjects randomized to Treatment (Lungpacer DPTS) as compared to subjects randomized to Control.

    "Successfully weaned" is defined as passing the protocol-specific Ventilator Liberation Trial (VLT), or removed from MV, and not reintubated (subjects with an oral or nasal, endotracheal tube) or returned to MV (subjects with a tracheostomy) within 48 hours

    Time frame: Patients will be allowed to stay in the study for up to 30 (+2 days of follow up for adverse events) days if not removed from mechanical ventilation sooner

Secondary outcomes

  1. Days on mechanical ventilation

    Days on mechanical ventilation from randomization to removal from MV associated with successful weaning or Day 30, whichever comes first

    Time frame: from randomization to 30 days

  2. Changes in diaphragmatic thickening fraction on diaphragm ultrasound

    Evaluate difference in changes in diaphragmatic thickening fraction between study allocation groups from randomization to successful weaning or on day 30 whichever comes first;

    Time frame: to successful weaning or on day 30 which ever comes first.

  3. Changes in MIP

    Change in MIP from randomization to last available measure; Change in MIP over time from randomization (baseline).

    Time frame: to successful weaning, or on day 30, whichever comes first.

  4. Change in MIP

    Rate of MIP change per day from randomization (baseline) to last available measure;

    Time frame: to successful weaning, or on day 30 whichever comes first.

  5. Changes in RSBI

    Change in RSBI from randomization (baseline) to last available measure; Change in RSBI over time from randomization (baseline);

    Time frame: to successful weaning, or on day 30, whichever comes first

  6. Change in RSBI

    Rate of RSBI change per day from randomization (baseline) to last available measure;

    Time frame: to successful weaning, or on day 30, whichever comes first

  7. Mortality

    30-day mortality

    Time frame: on day 30

Other outcomes

  1. Weaning from and re-installation of Mechanical Ventilation in both groups

    Cessations and re-instatements of mechanical ventilation to Day 30 or Study Exit

    Time frame: from randomization to 30 days

  2. Tracheostomy

    Proportion of subjects tracheotomized from randomization to study exit

    Time frame: from randomization to 30 days

  3. Ventilator settings

    Pressure Support daily, to last available measure

    Time frame: from randomization to 30 days

  4. Ventilator settings

    PEEP daily, to last available measure

    Time frame: from randomization to 30 days

  5. Ventilator settings

    Ventilation Mode daily, to last available measure

    Time frame: from randomization to 30 days

  6. Ventilator settings

    Tidal Volume daily, to last available measure

    Time frame: from randomization to 30 days

  7. Number of ICU admissions and discharges through D30 for both groups

    ICU admissions and discharges to day 30

    Time frame: from randomization to 30 days

  8. Number of hospital admissions and discharges through D30 for both groups

    Hospital admissions and discharges to day 30.

    Time frame: from randomization to 30 days

07

Study locations

21 sites
  • CHU Angers, Reanimation Medicale
    Angers, 49933, France
  • Hopital Louis-Mourier
    Colombes, 92700, France
  • CHU Montpellier
    Montpellier, France
  • Centre Hospitalier Universitaire de Nice (CHU Nice)
    Nice, 06001, France
  • Hopital Europeen Georges-Pompidou
    Paris, 75015, France
  • Pitie Salpetriere Hospital
    Paris, 75651, France
  • Centre Hospitalier Universitaire CHU
    Strasbourg, 67000, France
  • Uniklinik RWTH Aachen
    Aachen, 52074, Germany
  • Heart and Diabetes Center Bad Oeynhausen
    Bad Oeynhausen, 32545, Germany
  • Charite Universitatsmedizin Berlin - Mitte campus
    Berlin, 10117, Germany
  • Universitatsklinikum Bonn
    Bonn, 53105, Germany
  • Universitatsklinik Dresden
    Dresden, 01307, Germany
  • Universitatsmedizin Gottingen, Georg-August-Universitat
    Gottingen, 37075, Germany
  • Asklepios Kliniken Hamburg GmbH - Asklepios Klinikum Harburg
    Hamburg, 21075, Germany
  • Universitätsklinikum Hamburg-Eppendorf (UKE)
    Hamburg, Germany
  • Med Uni-Heidelberg
    Heidelberg, 69126, Germany
  • Universitätsklinikum Jena
    Jena, Germany
  • Klinikum Nuernberg
    Nuernberg, 90419, Germany
  • Universitatsklinikum Regensburg
    Regensburg, 93053, Germany
  • Fachkrankenhaus Kloster Grafschaft
    Schmallenberg, Germany
  • Wissenschaftliches Institut Bethanien fur Pneumologie e.V.
    Solingen, 42699, Germany
08

References and documents

Publications

  • Evans D, Shure D, Clark L, Criner GJ, Dres M, de Abreu MG, Laghi F, McDonagh D, Petrof B, Nelson T, Similowski T. Temporary transvenous diaphragm pacing vs. standard of care for weaning from mechanical ventilation: study protocol for a randomized trial. Trials. 2019 Jan 17;20(1):60. doi: 10.1186/s13063-018-3171-9. PubMed 30654837 ↗
  • Dres M, de Abreu MG, Merdji H, Muller-Redetzky H, Dellweg D, Randerath WJ, Mortaza S, Jung B, Bruells C, Moerer O, Scharffenberg M, Jaber S, Besset S, Bitter T, Geise A, Heine A, Malfertheiner MV, Kortgen A, Benzaquen J, Nelson T, Uhrig A, Moenig O, Meziani F, Demoule A, Similowski T; RESCUE-2 Study Group Investigators. Randomized Clinical Study of Temporary Transvenous Phrenic Nerve Stimulation in Difficult-to-Wean Patients. Am J Respir Crit Care Med. 2022 May 15;205(10):1169-1178. doi: 10.1164/rccm.202107-1709OC. PubMed 35108175 ↗

Individual participant data

Plan to share: Undecided — Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study and it will be available through the clinical research organization (CRO).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2019, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2017
First posted
Mar 30, 2017
StartActual
Sep 14, 2017
Primary completionActual
Dec 29, 2019
CompletionActual
Jan 30, 2020
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03096639
Lead sponsor
Lungpacer Medical Inc.
Collaborators
Syntactx
Responsible party
Sponsor
First posted
Mar 30, 2017
Start date
Sep 14, 2017
Primary completion
Dec 29, 2019
Completion
Jan 30, 2020
Last update
Nov 16, 2022

Study contacts

Linda H Clark, BSN
study director · Vice President of Clinical Affairs, Lungpacer Medical, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion